A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors

I. A. Grant, C. O. Rodriguez, Michael S Kent, G. Sfilgoi, I. Gordon, G. Davis, L. Lord, Cheryl A. London

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

Background: Few effective drugs are available to treat dogs with locally aggressive or metastatic mast cell disease. Hypothesis: Vinorelbine, a semisynthetic derivative of vinblastine, is an effective drug for the treatment of canine mast cell tumors (MCT). Animals: Twenty-four dogs with cutaneous MCT. Methods: Dogs with at least 1 measurable, cytologically confirmed, and previously untreated cutaneous MCT received a single treatment with vinorelbine at the previously established dosage of 15mg/m2 IV. Tumor measurements and CBC were evaluated before and 7 days after treatment. Adverse events were graded according to Veterinary Cooperative Oncology Group (VCOG) guidelines. Statistics: Data were accrued in accordance with a Simon's 2-stage design with a noninteresting response rate of .05, a target response of .25, and α and β values of .10. Results: Three of 24 dogs (13%) had a response to treatment, including 1 measurable complete response and 1 measurable partial response. The 3rd dog had microscopic complete response to treatment with stable measurable disease. Twenty other dogs (83%) had stable disease and 1 dog (4%) had progressive disease. Neutropenia occurred in 13 dogs (54%) (grade 1, n = 4; grade 3, n = 6; grade 4, n = 3). Gastrointestinal toxicity occurred in 11 dogs (46%) (anorexia: grade 1, n = 3; grade 2, n = 1; grade 3, n = 1; diarrhea: grade 1, n = 2; grade 3, n = 1; vomiting: grade 1, n = 5; grade 3, n = 1). Conclusions and Clinical Importance: Vinorelbine was associated with an overall response rate of 13% and a high prevalence of neutropenia. Additional studies are indicated to determine if repeated dosing of vinorelbine or combination of vinorelbine with other drugs increases the observed biologic activity against canine MCT.

Original languageEnglish (US)
Pages (from-to)388-393
Number of pages6
JournalJournal of Veterinary Internal Medicine
Volume22
Issue number2
DOIs
StatePublished - Mar 2008

Keywords

  • Chemotherapy
  • Navelbine
  • Vinca alkaloid

ASJC Scopus subject areas

  • veterinary(all)

Fingerprint Dive into the research topics of 'A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors'. Together they form a unique fingerprint.

  • Cite this

    Grant, I. A., Rodriguez, C. O., Kent, M. S., Sfilgoi, G., Gordon, I., Davis, G., Lord, L., & London, C. A. (2008). A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors. Journal of Veterinary Internal Medicine, 22(2), 388-393. https://doi.org/10.1111/j.1939-1676.2008.0051.x